Labcorp Plasma Complete

Laboratory Corporation of America has launched Labcorp Plasma Complete, a circulating tumor DNA-based genomic profiling test for patients with solid tumors. Oncologists can use the liquid biopsy test to perform a genomic profile of patients from a blood draw to inform personalized treatment plans. The test detects genomic alterations in ctDNA in 521 genes, including single-nucleotide variants and insertions and deletions, as well as amplifications in 12 genes, translocations associated with 12 genes, and microsatellite instability-high status, Labcorp said. The assay covers established and emerging biomarkers linked to therapies approved by the US Food and Drug Administration, guideline-driven therapies, and clinical trial eligibility. It offers a reportable range with a variant allele frequency as low as .10 percent and a specificity greater than 99.99 percent, Labcorp said.